Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ain Holdings Inc. is active in the Biotechnology & Pharmaceuticals technology area and currently has 1 pending office action. This action is being handled by 1 distinct examiner, ARIANI, KADE. The presence of only 1 pending office action indicates that the company's current prosecution activity is concentrated on a single application. This allows for a focused approach to the specific examination requirements of 1 individual.
The pending matter is located within 1 distinct art unit. This suggests that the technical subject matter of the 1 pending office action is categorized within a specific niche of the Biotechnology & Pharmaceuticals field. The individual identified as the busiest examiner for the portfolio is the only examiner currently assigned to a pending case. This person is responsible for 1 pending office action.
Because the total number of pending office actions is 1, ARIANI, KADE manages the company's entire current pending workload. Practitioners should focus their strategy on the specific feedback provided by this 1 distinct examiner. The alignment of 1 distinct art unit and 1 distinct examiner represents a highly centralized prosecution path for the company at this time.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARIANI, KADE | 1 | 75.0% | +32.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18838656 | SKIN IMPROVING AGENT CONTAINING FERMENTED EXTRACT AS MAIN RAW MATERIAL | ARIANI, KADE | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18838656 | SKIN IMPROVING AGENT CONTAINING FERMENTED EXTRACT AS MAIN RAW MATERIAL | ARIANI, KADE | 1651 | §102 | Non-Final OA | — | Pending | Aug 15, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAin Holdings Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kade Ariani has the most, with 1 of Ain Holdings Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
